Interleukin-28B polymorphisms on the SVR in the treatment of naive chronic hepatitis C with pegylated interferon-α plus ribavirin: A meta-analysis

被引:13
|
作者
Shi, Ke-Qing [1 ]
Liu, Wen-Yue [2 ]
Lin, Xian-Feng [2 ]
Fan, Yu-Chen [3 ]
Chen, Yong-Ping [1 ]
Zheng, Ming-Hua [1 ]
机构
[1] Wenzhou Med Coll, Inst Hepatol, Affiliated Hosp 1, Dept Infect & Liver Dis,Liver Res Ctr, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Coll, Sch Clin Med Sci 1, Wenzhou 325000, Peoples R China
[3] Shandong Univ, Qilu Hosp, Dept Hepatol, Jinan 250012, Peoples R China
关键词
Interleukin-28B; Single nucleotide polymorphisms; Hepatitis C virus; Systematic review; Sustained virological response; SUSTAINED VIROLOGICAL RESPONSE; VIRUS GENOTYPE 2; GENETIC-VARIATION; IL28B; THERAPY; ASSOCIATION; INFECTION; PREDICTION; CLEARANCE; 28B;
D O I
10.1016/j.gene.2012.07.026
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
There are accurate but inconclusive data on the association between single nucleotide polymorphisms (SNPs) of interleukin (IL)-28B and sustained virological response (SVR) in chronic hepatitis C (CHC). This meta-analysis aimed to derive a more precise estimation of the effects of IL-28B SNPs locus (rs12979860 and rs8099917) on SVR in naive CHC patients receiving pegylated interferon alpha (PEG-IFNI-cc) plus ribavirin. Literature search was conducted up to June, 2011, in PubMed, EMBASE and Cochrane Database of Systematic Reviews. A total of 36 studies involving 10912 cases with CHC receiving PEG-IFN-alpha plus ribavirin met the inclusion criteria. Analyses were stratified either by ethnicity or genotype of hepatitis C virus. In genotype 1/4 patients, rs12979860 CC was associated with high SVR in CHC patients (Caucasian: odds ratio (OR), 4.567; 95% confidence interval (CI), 3.826-5.452; Asian: OR, 4.033; 95%CI, 3.050-5.333; African American: OR, 4.297; 95%CI, 2.168-8.515; Hispanics: OR, 4.350; 95%CI, 2.817-6.717) but had no effect in genotype 2/3. In Caucasian (genotype 1/4: OR, 2.542; 95%CI, 2.108-3.065; genotype 2/3: OR, 1.363; 95%CI, 1.020-1.820) and Asian (genotype 1/4: OR, 5.214; 95%CI, 3.694-7.360; genotype 2/3: OR, 1.785; 95%CI, 1.095-2.910), rs8099917 TT was associated with high SVR in both genotype 1/4 and 2/3. Meta-regression showed that in Caucasians with CHC genotype 1/4, gender male might contribute to the effect of rs12979860 on SVR but advanced fibrosis might weaken this effect. Furthermore, in Asians with CHC genotype 1/4, high baseline viral load and advanced fibrosis might also undermine the effect of rs8099917 on SVR. This meta-analysis suggested that IL-28B rs12979860 CC and rs8099917 TT were associated with high SVR rate in CHC genotype 1/4. In CHC genotype 2/3, rs8099917 TT carriers also had higher SVR. Crown Copyright (C) 2012 Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:27 / 35
页数:9
相关论文
共 50 条
  • [31] Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C
    PN Rao
    Abraham Koshy
    Jacob Philip
    Narayanan Premaletha
    Joy Varghese
    Krishnasamy Narayanasamy
    Samir Mohindra
    Nitin Vikas Pai
    Manoj Kumar Agarwal
    Ashokna Konar
    Hasmukh B Vora
    World Journal of Hepatology, 2014, (07) : 520 - 526
  • [32] Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy
    Liang, C. -M.
    Hu, T. -H.
    Lu, S. -N.
    Hung, C. -H.
    Huang, C. -M.
    Wang, J. -H.
    Yen, Y. -H.
    Chen, C. -H.
    Chang, K. -C.
    Tsai, M. -C.
    Kuo, Y. -H.
    Lee, C. -M.
    JOURNAL OF VIRAL HEPATITIS, 2013, 20 (11) : 761 - 769
  • [33] Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation
    Kawaoka, Tomokazu
    Takahashi, Shoichi
    Takaki, Shintaro
    Hiramatsu, Akira
    Waki, Koji
    Hiraga, Nobuhiko
    Miki, Daiki
    Tsuge, Masataka
    Imamura, Michio
    Kawakami, Yoshiiku
    Aikata, Hiroshi
    Ochi, Hidenori
    Onoe, Takashi
    Tashiro, Hirotaka
    Ohdan, Hideki
    Chayama, Kazuaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (09) : 1467 - 1472
  • [34] Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C
    Rao, P. N.
    Koshy, Abraham
    Philip, Jacob
    Premaletha, Narayanan
    Varghese, Joy
    Narayanasamy, Krishnasamy
    Mohindra, Samir
    Pai, Nitin Vikas
    Agarwal, Manoj Kumar
    Konar, Ashoknanda
    Vora, Hasmukh B.
    WORLD JOURNAL OF HEPATOLOGY, 2014, 6 (07) : 520 - 526
  • [35] Role of Interleukin-28B Genetic Polymorphisms in Korean Patients with Hepatitis C Virus Infection
    Kil, Ho
    Jeong, Sook-Hyang
    Kim, Jin-Wook
    Byoun, Young Sang
    Min, Bo Young
    Woo, Byung-Hyun
    Lee, Youn Jae
    Kim, Young Seok
    GUT AND LIVER, 2014, 8 (01) : 70 - 78
  • [36] Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and meta-analysis
    Hartwell, Debbie
    Shepherd, Jonathan
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 (01) : 56 - 62
  • [37] Neutralizing Antibodies to Interferon-α and Circulating Interferon in Patients With Chronic Hepatitis C Non-Responding to Pegylated Interferon Plus Ribavirin Re-Treated by Pegylated Interferon-α-2a and Ribavirin (ANRS HC16 GAMMATRI Substudy)
    Halfon, Philippe
    Perusat, Sophie
    Bourliere, Marc
    Bronowicki, Jean-Pierre
    Trimoulet, Pascale
    Benhamou, Yves
    Leroy, Vincent
    Marcellin, Patrick
    Foucher, Juliette
    Penaranda, Guillaume
    Chene, Genevieve
    Couzigou, Patrice
    JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (12) : 2027 - 2031
  • [38] Dose comparison study of pegylated interferon-α-2b plus ribavirin in naive Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial
    Kawaoka, Tomokazu
    Kawakami, Yoshiiku
    Tsuji, Keiji
    Ito, Hiroyuki
    Kitamoto, Mikiya
    Aimitsu, Shiomi
    Kawakami, Hiroiku
    Jeong, Soo Cheol
    Imamura, Michio
    Aikata, Hiroshi
    Takahashi, Shoichi
    Chayama, Kazuaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (03) : 366 - 371
  • [39] IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection
    Chen, J-Y
    Lin, C-Y
    Wang, C-M
    Lin, Y-T
    Kuo, S-N
    Shiu, C-F
    Chang, S-W
    Wu, J.
    Sheen, I-S
    GENES AND IMMUNITY, 2011, 12 (04) : 300 - 309
  • [40] Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks
    Wada, Yuki
    Tamai, Hideyuki
    Uno, Akiko
    Kawashima, Akira
    Shingaki, Naoki
    Mori, Yoshiyuki
    Moribata, Kosaku
    Miyata, Kaori
    Higashi, Katsuhiko
    Deguchi, Hisanobu
    Ueda, Kazuki
    Inoue, Izumi
    Maekita, Takao
    Iguchi, Mikitaka
    Kato, Jun
    Ichinose, Masao
    HEPATOLOGY RESEARCH, 2014, 44 (02) : 179 - 186